Skip to main content

Altimmune, Inc. (ALT)

NASDAQ: ALT · IEX Real-Time Price · USD
10.42 -0.01 (-0.10%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap414.08M
Revenue (ttm)3.45M
Net Income (ttm)-83.82M
Shares Out39.74M
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume670,903
Open10.76
Previous Close10.43
Day's Range10.20 - 10.70
52-Week Range8.10 - 24.61
Beta1.40
AnalystsStrong Buy
Price Target30.71 (+194.7%)
Earnings DateNov 10, 2021

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i...

IndustryBiotechnology
CEOVipin Garg
Employees43
Stock ExchangeNASDAQ
Ticker SymbolALT
Full Company Profile

Financial Performance

In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 30.71, which is an increase of 194.72% from the latest price.

Price Target
$30.71
(194.72% upside)
Analyst Consensus: Strong Buy

News

Altimmune to Present at Upcoming Investor and Scientific Conferences

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be pres...

5 days ago - GlobeNewsWire

Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be pres...

2 weeks ago - GlobeNewsWire

Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment

2 weeks ago - GlobeNewsWire

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial resul...

3 weeks ago - GlobeNewsWire

Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contac...

1 month ago - PRNewsWire

Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting vir...

1 month ago - GlobeNewsWire

Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on ...

GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its ...

1 month ago - GlobeNewsWire

H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off

H.C. Wainwright said that Altimmune Inc (NASDAQ:ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients.  However, shares dropped, which he sees primarily b...

1 month ago - Benzinga

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34

Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.

1 month ago - InvestorPlace

Why Altimmune Stock Is Under Pressure Today

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

1 month ago - The Motley Fool

See Why Altimmune Stock Plunged After Obesity Trial Data

Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 weeks, ...

1 month ago - Benzinga

Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and O...

GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidu...

1 month ago - GlobeNewsWire

Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 ...

2 months ago - GlobeNewsWire

Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...

2 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September

3 months ago - GlobeNewsWire

Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial resu...

3 months ago - GlobeNewsWire

Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Wall Street Heads Into H2 With Stocks on a Streak

Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.

Other symbols:GOOGLJNJWBA
4 months ago - Schaeffers Research

Why Altimmune Is Crashing Today

The company halts development on both a COVID-19 vaccine and a drug targeting the disease.

4 months ago - The Motley Fool

ALT in Freefall After Covid-19 Vaccine Trials Scrapped

Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development ...

4 months ago - Schaeffers Research

Altimmune Stock Tanks On Double Bad News From COVID-19 Program

Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-d...

4 months ago - Benzinga